Loading viewer...
investor_presentation
Format: PDF investor_presentation
Fennec Pharmaceuticals is a commercial-stage biotechnology company focused on pediatric cancer treatments. The presentation covers PEDMARK®, an FDA-approved medication to reduce hearing loss from cisplatin chemotherapy in pediatric patients, which launched in the U.S. in October 2022. The company has secured 7 years of U.S. market exclusivity and recently obtained EU and UK approvals with 10 years of E.U. exclusivity.
presentation
investor_presentation
33 Pages
Shopify
Malita Investments Rights Issue 2024
investor_presentationinvestor_presentation
24 Pages
Malita Investments plc